ARISE - Losmapimod
Research type
Research Study
Full title
Anti-inflammatories to Reverse Immune Senescence in the Elderly (ARISE)- Losmapimod.
IRAS ID
179310
Contact name
Arne Akbar
Contact email
Sponsor organisation
University College London
Duration of Study in the UK
1 years, 11 months, 31 days
Research summary
As people get older, changes in the immune system lead to more frequent infectious diseases and less benefit from vaccination. The tuberculin skin test (TST), intradermal injection of killed Varicella Zoster virus (VZV) and the cantharidin skin blister provide a strategy to test human immune responses and have previously been used to show immune responses are diminished and inflammation levels are increased in the elderly. The aim of this study is to increase our understanding of how and why the immune system changes in older humans, by comparing the primary immune responses to tuberculin, secondary immune responses to VZV, and non-specific inflammation in the cantharadin skin blister model following administration of losmapimod, a drug to selectively suppress inflammation to enhance antigen-specific immunity in older humans. The new data will be used to inform new strategies to improve immune responses associated with ageing.
REC name
London - Bromley Research Ethics Committee
REC reference
15/LO/1539
Date of REC Opinion
26 Oct 2015
REC opinion
Further Information Favourable Opinion